TY - JOUR
AU - Lederman, Michael M.
AB - 1 AUGUST Correspondence Appropriate Use of Nevirapine excluded patients with CD4 cell counts patients were not monitored for the ap- for Long-Term Therapy 3 !200 cells/mm , the major predictive fac- pearance of rash or hepatotoxicity until tor of hepatic events was removed from after 4 weeks of treatment. This is insuf- To the Editor—The recent article by consideration, therein biasing the au- ficient, according to current recommen- Sanne et al. [1] described possible risk fac- thors’ conclusion that a low body mass dations, especially given that the majority tors associated with hepatic adverse events index (BMI) is predictive of nevirapine of these events occur during the first 6 that can occur while nevirapine is being hepatotoxicity. weeks of treatment. Likewise, prompt taken in a clinical trial. We are concerned Additionally, there was only a small discontinuation of nevirapine is recom- about several key issues either overlooked number of patients with BMIs !18.5 mended after the onset of grade 3 or 4 or minimized in the article. It is impor- (4.4% of total), and these accounted for rash or constitutional symptoms sug- tant to understand that the prelimi- only a small proportion of patients with gestive of hepatitis. It 
TI - Reply to Leith et al.
JF - Journal of Infectious Diseases
DO - 10.1086/431608
DA - 2005-08-01
UR - https://www.deepdyve.com/lp/oxford-university-press/reply-to-leith-et-al-hYW6A02ctr
SP - 546
EP - 547
VL - 192
IS - 3
DP - DeepDyve
ER -